Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

Abstract Background To evaluate the long-term efficacy, safety and immunogenicity of continuing LBEC0101; the etanercept (ETN) biosimilar; or switching from the ETN reference product (RP) to LBEC0101 in patients with rheumatoid arthritis (RA). Methods This multicentre, single-arm, open-label extensi...

Full description

Bibliographic Details
Main Authors: Min-Chan Park, Hiroaki Matsuno, Jinseok Kim, Sung-Hwan Park, Sang-Heon Lee, Yong-Beom Park, Yun Jong Lee, Sang-Il Lee, Won Park, Dong Hyuk Sheen, Jung-Yoon Choe, Chan-Bum Choi, Seung-Jae Hong, Chang-Hee Suh, Shin-Seok Lee, Hoon-Suk Cha, Bin Yoo, Jin-Wuk Hur, Geun-Tae Kim, Wan-Hee Yoo, Han Joo Baek, Kichul Shin, Seung Cheol Shim, Hyung-In Yang, Hyun Ah Kim, Kyung-Su Park, In Ah Choi, Jisoo Lee, Masato Tomomitsu, Seonghye Shin, Jiyoon Lee, Yeong Wook Song
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Arthritis Research & Therapy
Subjects:
Etanercept
LBEC0101
Rheumatoid arthritis
Biosimilar
Switch
Online Access:http://link.springer.com/article/10.1186/s13075-019-1910-2

Internet

http://link.springer.com/article/10.1186/s13075-019-1910-2

Similar Items